Ososayensi abavela ezinkampanini ezimbili bahlaziye ukulandelana kwe-SARS-CoV-2 Omicron ehlukile, ukulandelana kwegciwane okukhethiwe, kanye nama-clone e-plasmid aklanywe. Silindele ukuthi imithi yokugoma emisha ye-Omicron SARS-CoV-2 ingathuthukela ekuhlolweni komtholampilo esikhathini esingaphansi kwezinsuku eziyi-100.
“Sikholelwa ukuthi kubalulekile ukwenza imigomo emisha ngokushesha nangempumelelo ukuze kuliwe nokwehluka okusha kwe-Omicron COVID-19. Sizosebenzisana eduze nezinhlangano ezilawulayo futhi sifune izifundo zomtholampilo ezifanele kanye nezigunyazo zokulawula ukuze lethe lo mgomo emakethe ngokushesha okukhulu.” kusho uBrad Sorenson, oyi-CEO yeProvidence Therapeutics.
"Sibheke ngabomvu ukuthuthukisa ngokushesha lo mgomo omusha ohlukile we-Omicron nge-Providence, futhi ilethe inzuzo yalo mgomo kulezo zindawo ezifinyeleleka kancane ekwelashweni kwamanje komgomo we-mRNA." kuphawula u-Kerry Blanchard, MD, PhD, Isikhulu Esiphezulu se-Everest Medicines.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- “We look forward to rapidly developing this new Omicron variant vaccine with Providence, and bringing the benefit of this vaccine to those areas with lower accessibility to current mRNA vaccine treatments in particular.
- “We believe it is essential to develop new vaccines quickly and effectively to combat the new Omicron COVID-19 variant.
- We will work closely with regulatory bodies and seek the appropriate clinical studies and regulatory approvals to bring this vaccine to market as soon as possible.
